Top Biotech Companies (3,710)
We believe Cells can theoretically produce almost anything, from fabrics to food, fuel and medicines. Designing cell-factories is hard, but our tools and machine-learning models can make it easier. Our mission is to ultimately help replace traditional farms and factories for a more sustainable world. Jobs: https://jobs.cradle.bio
Imperative Care is a Silicon Valley-based medical technology company focused on developing the next generation of innovative solutions to address the vast and urgent needs in stroke intervention and peripheral thrombectomy. With a physician-driven approach and a culture of rapid innovation, we are working to improve every aspect of the stroke procedure with the goal of bringing patients the best...
Imperative Care's Top Stability & Growth Strengths
Investor Backing & Capital Strength: An oversubscribed Series E of up to $150M and prior nine‑figure rounds indicate strong investor confidence and funding to scale commercialization and R&D. Disclosures emphasize fresh capital explicitly earmarked to fuel “hypergrowth.”
Product Line Growth: Multiple recent FDA 510(k) clearances and launches expanded the Zoom Stroke System (including .088″ access-and-aspiration use, DuoPort/CDAT, and Zoom 7X) and extended the portfolio into PE with the Symphony system. Company-backed clinical data and real‑world presentations further support ongoing product adoption.
Future-Ready Strategy: A connected platform spans acute stroke (Zoom), peripheral thrombectomy (Imperative Care Vascular/Truvic), digital recovery (Kandu, merged with Neurolutions), and robotics (Telos), reinforced by partnerships such as Proximie. This breadth positions the company to address the full stroke/vascular continuum beyond single‑product offerings.
RoukenBio is an immunology-focused contract research organization (CRO) supporting biotherapeutic and pharmaceutical innovators from drug discovery through IND-enabling and pre-IND testing. It provides bespoke in vitro 2D and 3D cell-based models, immunology and bioassay research, cell engineering, translational systems, pharmacological characterization, and potency-assay development across inflammation, autoimmunity, immuno-oncology, oncology, and other therapeutic areas, serving global customers. Its vision is to...
Verity Pharmaceuticals is a specialty pharmaceutical company focused on commercializing therapeutically relevant prescription medicines, particularly those in short supply or absent from the healthcare environment.
Vow is a cultured meat company, founded and operated in Sydney, Australia. We’re a multidisciplinary team of scientists, technologists and designers, all working together to make sustainable food both irresistible and available to billions of people.
This page is intended for US audiences only. Tenpoint Therapeutics Limited is a commercial-ready biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts, and geographic atrophy. Its lead asset, BRIMOCHOL PF, is a novel, pupil-modulating investigational therapeutic designed to correct...
Tenpoint Therapeutics's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Investor backing is considered strong, with a $235M financing package (Series B plus credit facility) cited to accelerate commercialization. Feedback suggests this capital position enables scaling across commercialization and international expansion.
Market Expansion: Geographic reach is expanding through submissions in the UK and a partnership with Lupin/VISUfarma to commercialize YUVEZZI across Europe. Feedback suggests these moves broaden the company’s accessible markets beyond the U.S.
Product Line Growth: The portfolio is described as expanding, with YUVEZZI approved and additional preclinical programs targeting cataracts/presbyopia and geographic atrophy. Feedback suggests this pipeline progression supports continued growth potential.
Adjutant Solutions Group is a global engineering and business process management consultancy specializing in regulated industries, particularly the pharmaceutical and medical device sectors. They partner with clients to orchestrate complex projects, focusing on the development, qualification, and commercialization of drug delivery systems and medical devices to help them reach the market faster and more efficiently.
Excel Scientific Inc. designs and manufactures microplate sealing films, foils, and custom laminate constructions for life-science and diagnostic applications. Its medical-grade products support PCR, qPCR, ELISA, cell culture, sample storage, point-of-care disposables, and microfluidic components. The company serves pharmaceutical and biotechnology firms, diagnostic OEMs, clinical laboratories, research organizations, and academic institutions, producing its solutions in the United States under an...
Scientific Protein Laboratories is a leading global supplier of high-quality active pharmaceutical ingredients (APIs). Specializing in cGMP biopharmaceutical manufacturing, the company is among the largest commercial suppliers of Heparin Sodium USP, Pancreatin USP, and Pancrelipase USP. Based in Waunakee, Wisconsin, it serves the pharmaceutical, veterinary, and food industries globally.
Drug Information Association (DIA) is a leading global multidisciplinary life science membership association. It mobilizes life science professionals across all areas of expertise to engage with patients, peers, and thought leaders in a neutral environment. DIA focuses on the discovery, development, regulation, surveillance, and marketing of healthcare products to advance the life sciences community.
Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens, and regulate immune function in autoimmune disease. The company’s proprietary DECODE™ platform provides a comprehensive understanding of the interactions between T cell receptors and their antigens in disease. DECODE uniquely elucidates the...
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of...
Eli Lilly and Company's Top Stability & Growth Strengths
Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.
Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.
Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
The Donald Danforth Plant Science Center is an independent nonprofit research institute focused on fundamental plant science and translating discoveries into useful crops and products. Its scientists study plant growth, energy capture, and disease resistance, while developing research-based solutions to global challenges. The Center’s work focuses on food security, improving human health, sustainable agricultural productivity, and environmental protection, with a...
Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
Tiens Europe GmbH is a multinational conglomerate established in the 1990s, operating in over 190 countries. The company integrates industrial, business, and financial capital to provide a wide range of health, wellness, beauty, and personal care products, including household items. It specializes in biotechnology and natural food supplements based on Traditional Chinese Medicine to promote optimal health and beauty.
Biorasi is a customer-focused, full-service, contract research organization (CRO) that delivers fast and flexible solutions across global clinical trials to maximize speed-to-market for its sponsors. As the leader in neurology, nephrology, dermatology, and the rare and urgent disease market, Biorasi sets new standards for speed, agility, and quality in patient enrollment, decentralized trials, and data transparency. It is Biorasi’s mission to...
theMednet is the premier peer-to-peer digital platform helping physicians unlock expert knowledge. Our mission is to facilitate knowledge and information sharing between physicians and help address disparities in patient care. theMednet is a physician-only network to access invaluable expert advice and request answers to real world clinical questions. All content serves as a resource for physicians to access expert knowledge, contribute...
Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia, focusing on maternal and fetal medicine to lower risks for mothers and babies.
Drug Hunter™ is an essential subscription service for R&D-focused organizations turning molecules into medicines. Every day, drug discovery strategies, tactics, challenges and solutions are disclosed, but the knowledge is fragmented across journals, conferences, patents, databases, news, company reports, filings and endless other sources, making it challenging to find and apply. Drug Hunter’s experts keep you current by connecting the dots, distilling industry...
